ArticleCurrent issues in molecular biology2025
Clinicopathological Implications of Maspin, CD8, and PD-L1 Expression in Liposarcomas.
Article in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liposarcomas, the most common subtype of soft tissue sarcomas, show variable biological behavior and therapeutic response. Programmed death-ligand 1 (PD-L1) and cytotoxic T lymphocyte marker CD8 have been implicated in tumor immune evasion and prognosis in various malignancies, while Maspin, a tumor suppressor, has shown a negative prognostic impact in sarcomas. This study aimed to investigate the clinicopathological significance of PD-L1, CD8, and Maspin expression in liposarcomas. A retrospective analysis of 42 liposarcoma cases diagnosed between 2016 and 2023 was conducted. Immunohistochemical staining for PD-L1 (using DAKO 22C3 and 28-8 clones), CD8, and Maspin was performed. PD-L1 expression was assessed using the tumor proportion score (TPS) and tumor cell score (TC). CD8 expression was evaluated using an H-score, and Maspin positivity was assessed based on subcellular localization. Correlations with clinicopathological parameters were statistically analyzed using chi-squared and Fisher's exact tests. Most liposarcomas exhibited low PD-L1 expression (<10%), but increased PD-L1 levels correlated with poor differentiation (G3), higher CD8 infiltration (H-score > 10%), and cytoplasmic Maspin positivity. Statistically significant associations were found between high PD-L1 expression and high CD8 infiltration (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.